Acumen Pharmaceuticals, Inc. (ABOS)

Market Cap	142.39M
Revenue (ttm)	n/a
Net Income (ttm)	-81.67M
Shares Out	60.08M
EPS (ttm)	-1.37
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	180,507
Open	2.420
Previous Close	2.390
Day's Range	2.320 - 2.430
52-Week Range	2.080 - 5.090
Beta	0.04
Analysts	Strong Buy
Price Target	9.00 (+279.75%)
Earnings Date	Nov 12, 2024

About ABOS

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 1, 2021
• Employees: 52
• Stock Exchange: NASDAQ
• Ticker Symbol: ABOS
• Website: https://acumenpharm.com

Analyst Forecast

According to 4 analysts, the average rating for ABOS stock is "Strong Buy." The 12-month stock price forecast is $9.0, which is an increase of 279.75% from the latest price.

Price Target

$9.0

(279.75% upside)

Analyst Consensus: Strong Buy